SG
PVLA

Strid Group’s Palvella Therapeutics PVLA Stock Holding History

Strid Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,166
Closed -$409K – 75
2025
Q2 		$409K Sell
18,166
-11,053
-38% -$259K 0.06% 51
2025
Q1 		$818K Buy
+29,219
New +$563K 0.13% 31

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Strid Group's PVLA Position: Q3 2025 in Review

Strid Group sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 18,166 shares — an estimated $409K sold.

Strid Group first reported a position in PVLA in Q1 2025 and held it in 2 quarters. The position peaked at $818K in Q1 2025. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

  • Strid Group reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Strid Group sold 18,166 Palvella Therapeutics shares in Q3 2025, an estimated $409K.
  • Strid Group first reported a position in Palvella Therapeutics in Q1 2025 and held it in 2 quarters.
  • Strid Group's Palvella Therapeutics position peaked at $818K in Q1 2025.
  • 100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on Strid Group's 13F filing for Q3 2025, filed 15 Oct 2025.